Genitourinary Cancer Clinical Trials

The most recent listing of current clinical trials for genitourinary cancers — including prostate, bladder, testicular and kidney — appears below. 

Site: Genitourinary (Includes Prostate, Bladder, Testicular and Kidney)

Protocol ID    Title

ARGOS-AGS-003-007-ADAPT    An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

BNIT-PRV-301-PROSTVAC    A Randomized, Double-Blind, Phase 3 Efficacy Trial of PROSTVAC± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Adenocarcinoma of the Prostate

CALGB-90601    A Randomized Double-Blind Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma

ECOG-1808    A Randomized Phase II Trial of Sunitinib/ Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features

ECOG-E2810    Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Subjects with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy

EXELIXIS-XL-184-306    A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer

HOG-GU12-160    A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination with OGX-427 in Patients with Relapsed or Refractory Metastatic Urothelial Carcinoma after Receiving a Platinum-containing Regimen Hoosier Oncology Group GU12-160; The Borealis-2 Clinical Trial

IIT-BYLOW-HMB    Use Of ß-Hydroxy-ß-Methylbutyrate (HMB) To Counteract Loss Of Muscle Mass And Strength In Older Men With Recurrent Prostate Cancer Started On Androgen Deprivation Therapy (ADT)

IIT-LAWTON-FOLKMAN-SIB    A Phase II Trial of High-Dose Pelvic Lymph Node IMRT (Intensity Modulated Radiation Therapy) and Hypofractionated Prostate IMPRT for High Risk Prostate Cancer Patients

IIT-LANGENSTROER-KIM-1    Assessment of Kidney Injury Molecule (KIM-1) as a Marker of Ischemic Acute Injury Post Kidney Surgery

RTOG-0815    A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer

RTOG-0924    Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

RTOG-0926    A Phase II Protocol For Patients With Stage T1 Bladder Cancer To Evaluate Selective Bladder Preserving Treatment By Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following A Thorough Transurethral Surgical Re-Staging

RTOG-1115    Phase III Trial Of Dose Escalated Radiation Therapy And Standard Androgen Deprivation Therapy (ADT) With A GNRH Agonist Vs. Dose Escalated Radiation Therapy And Enhanced ADT With A GNRH Agonist And TAK-700 For Men With High Risk Prostate Cancer

SWOG-S0931    EVEREST EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study 

UC-09-128B    The Impact of a Decision Aid for Hormone Therapy for Prostate Cancer Recurrence on Patients Anxiety, Decisional Conflict, and Knowledge: A Randomized Trial